Flibanserin (Oral)

[14] The handling of missing data has also been elaborated upon in the same source.

Information & Authors

Additional efficacy outcomes encompassed the CFB in the Female Sexual Function Index (FSFI) desire domain (FSFI-d) score, FSFI total score, Female Sexual Distress Scale-Revised (FSDS-R) Item 13 score, FSDS-R total score, Patient’s Global Impression of Improvement (PGI-I), and Patient Benefit Evaluation (PBE). Safety outcomes included any adverse event (AEs), drug-related AEs, serious AEs, severe AEs, AEs leading to study discontinuation, and common AEs, including dizziness, headache, fatigue, nausea, somnolence, and insomnia. The analyses of the efficacy outcomes were stratified according to the menstrual status of the subjects (premenopausal or postmenopausal) and the dose of flibanserin. Safety outcomes were stratified according to the dose of flibanserin. Data extraction was independently conducted by 5 review authors using standardized data extraction forms, with details provided elsewhere. [14] Five authors independently performed the risk of bias assessment using

Product	Dosage	Quantity + Bonus	Price
Viagra Professional	100mg	270 + 6 Pills	456.97€ 435.21€	Buy
Kamagra Gold	100 mg	12 Pills	55.64€ 52.99€	Buy
Tadalista Super Active	20mg	270 + 30 Pills	661.49€ 629.99€	Buy
Cialis Generic	20mg	20 Pills	54.72€ 52.11€	Buy
Kamagra Gold	50 mg	12 Pills	47.30€ 45.05€	Buy
Viagra Oral Jelly	100mg	220 + 18 Sachets	562.28€ 535.50€	Buy
Kamagra Effervescent Tablets	100 mg	84 + 7 Pills	202.91€ 193.25€	Buy
Kamagra Soft Tabs	100 mg	84 + 4 Pills	233.05€ 221.95€	Buy
Viagra Generic	200mg	20 Pills	61.69€ 58.75€	Buy
Cialis Generic	10mg	20 Pills	48.23€ 45.93€	Buy
Cialis Generic	10mg	90 + 6 Pills	146.17€ 139.21€	Buy

the risk of bias tool in Review Manager (RevMan) Web 2023 Version.

What is Addyi (flibanserin)?

These trials demonstrated statistically male enhancement pill significant enhancements in sexual desire, desire-related distress, and the frequency of satisfying sexual events (SSE) when administered at a dosage of 100 mg (daily at bedtime) compared to a placebo. [6] Common adverse events of flibanserin include dizziness, somnolence, nausea, fatigue, insomnia, and dry mouth. [1,5,6] Coadministration of alcohol may increase the incidence of sedation-, hypotension-, and syncope-related adverse events of flibanserin. Many randomized controlled trials (RCTs) and observational studies have reported the efficacy and safety of flibanserin in pre- and postmenopausal women with HSDD, and there are marked heterogeneities in the efficacy and safety outcomes data. Although some meta-analyses and pooled analyses have been conducted to summarize the efficacy and safety of flibanserin, they have not included all available RCTs to date.

Pharmacogenetic associations and support therapeutic management recommendations

Those meta-analyses did not perform separate analyses of flibanserin’s efficacy and safety in pre- and postmenopausal women and for flibanserin 50 and 100 mg.[8–12] Consequently, it became imperative to conduct a new meta-analysis incorporating the findings of the latest RCTs to gain a more comprehensive understanding of the efficacy and safety of flibanserin in women with HSDD. This meta-analysis complied with the guidelines outlined in the Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklists. [13] The predetermined protocol has been officially recorded in PROSPERO, with a registration number CRD42023471856, and is accessible online. Since ethical approval was already granted for the individual studies, there wasn’t any need for additional approval for this meta-analysis. A thorough investigation was conducted by searching multiple databases and registers, such as MEDLINE (via PubMed), Scopus, Google Scholar, Cochrane Central Register, and ClinicalTrials.gov. Specific biases have been outlined in the same source.

Pros and cons of Addyi (flibanserin)

RCTs involving women with HSDD receiving flibanserin in the intervention arm and placebo in the control arm were sought after throughout the electronic databases. The primary outcomes were the changes from baseline in satisfying sexual events (SSE) per month and sexual desire score per month measured using an electronic diary (eDiary). From 478 initially screened articles, data from 8 RCTs involving 7906 women with HSDD were analyzed. In premenopausal women, flibanserin 100 mg was superior to placebo in improving the number of SSE per month (mean difference, MD 0.69, 95% CI [0.39, 0.99]), eDiary sexual desire score (MD 1.71, 95% CI [0.43, 2.98]), Female Sexual Function Index (FSFI) desire domain (FSFI-d) score (MD 0.30, 95% CI [0.29, 0.31]), FSFI total score (MD 2.51, 95% CI [1.47, 3.55]), Female Sexual Distress Scale-Revised (FSDS-R) Item 13 score (MD −0.30, 95% CI [−0.31, −0.29]), and FSDS-R total score (MD −3.30, 95% CI [−3.37, −3.23]). Compared to placebo, a higher number of premenopausal women using flibanserin 100 mg achieved improvements in the Patient’s Global Impression of Improvement score (OR 1.93, 95% CI [1.58, 2.36], P < .00001) and responded positively at Patient Benefit Evaluation (PBE) (odds ratio, OR 1.76, 95% CI [1.34, 2.31], P < .0001).

Dosage and Administration

Postmenopausal women receiving flibanserin 100 mg also benefited in terms of the number of SSE per month, FSFI-d and total scores, FSDS-R Item 13 and total scores, and PBE response. Although flibanserin use was associated with higher risks of dizziness, fatigue, nausea, somnolence, and insomnia, these adverse events were mild in nature; the serious AEs and severe AEs were comparable between the flibanserin and placebo groups. While flibanserin has demonstrated efficacy in the treatment of HSDD in both pre- and postmenopausal women, its therapeutic advantages may be overshadowed by the higher likelihood of AEs. Female sexual dysfunction (FSD) is common, even more common than male sexual dysfunction. There is limited data on the incidence and prevalence of FSD. Outcomes were expressed as mean differences (MD) for continuous variables.

• The prescribing guidelines emphasize cautious use in women on other psychotropic drugs.
• Flibanserin's approval was driven by a need for female-specific sexual health medications.
• Its mechanism involves serotonergic pathways impacting sexual response.
• The drug is typically part of a broader therapy including counseling or therapy.
• Studies indicate a small but statistically significant benefit for some women.
• It is important to rule out other medical or psychological causes before use.
• Flibanserin is contraindicated with certain medications, such as CYP3A4 inhibitors.
• Side effect management includes monitoring blood pressure and mental status.
• The medication's role is to improve quality of life by addressing sexual desire challenges.

The results were reported as odds ratios (ORs) or risk

Desire Starts in the Brain...

Received: 19 March 2024 / Received in final form: 23 May 2024 / Accepted: 24 May 2024 The authors have no funding and conflicts of interest to disclose. All data generated or analyzed during this study are included in this published article [and its supplementary information files]. Supplemental Digital Content is available for this article. How to cite this article: Kamrul-Hasan ABM, Hannan MA, Alam MS, Aalpona FTZ, Nagendra L, Selim S, Dutta D. Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis.

What should I tell my healthcare provider before using Addyi?

Kamrul-Hasan, Department of Endocrinology, Mymensingh Medical College, Mymensingh Sadar, Mymensingh 2200, Bangladesh (e-mail: [email protected]). This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. Flibanserin, approved for the treatment of hypoactive sexual desire disorder (HSDD) in females, has demonstrated diverse therapeutic and adverse effect (AE) prospects in the extant randomized controlled trials (RCTs). This meta-analysis aimed to characterize the outcomes of flibanserin use in these patients comprehensively. ratios (RRs) with 95% confidence intervals (CIs) for binary outcomes.

• The chemical name is 1,2,3,4-tetrahydro-1-{[2-(1,2,3,4-tetrahydro-8-quinolyl)ethyl]amino}methyl-6-fluorobenz[cd]indol-5(6H)-one.
• Molecular formula is C₂₀H₂₁F₃N₄O.
• It is a white to off-white powder that is slightly soluble in water.
• The tablet contains inactive ingredients: microcrystalline cellulose, croscarmellose sodium.
• Also contains magnesium stearate, hypromellose, titanium dioxide, and iron oxide red.
• Manufactured under strict Good Manufacturing Practice (GMP) standards.
• Distributed in bottles or blister packs, typically containing 30 tablets.
• National Drug Code (NDC) for Addyi 100 mg is 0187-XXXX-XX (varies by pack).
• Keep out of reach of children and pets.

The data was aggregated, employing random effect models to analyze the primary and secondary outcomes.

• Flibanserin acts as an agonist on dopamine receptors and antagonist on certain serotonin receptors.
• The medication can take several weeks to show benefits.
• It is not approved for use in postmenopausal women.
• Flibanserin was initially developed as an antidepressant.
• It has a pharmacokinetic profile with a half-life of around 13 hours.
• Dose adjustments are necessary for patients with liver impairment.
• The drug can cause hypotension, especially with alcohol or CYP3A4 inhibitors.
• Patients are monitored for side effects such as sleepiness and low blood pressure.
• Flibanserin's efficacy is moderate and varies among women.

The RevMan web platform (2023 version, developed by

Parameter	Description	Typical Values
Absorption	Rapid, high bioavailability	~52%
Peak Plasma Levels	1-2 hours after dosing	~1.5 hours
Half-life	Duration of effect	11 hours
Metabolism	Hepatic via CYP3A4	Major route
Excretion	Mainly via urine	87% in urine

Cochrane, based in Oxford, UK) enabled the comparison of MD for primary and secondary outcomes between the flibanserin

Other uses for this medicine

The search covered the period from these sources’ inception until January 20, 2024. The search strategy utilized a Boolean approach with the terms (flibanserin) AND (hypoactive sexual desire disorder) OR (female sexual interest/arousal disorder); the search terms were applied to titles only. A thorough and careful search was conducted to find any recently published or unpublished clinical trials in English. This search included examining references within the RCTs included in this study and relevant journals. The selection of RCTs for this meta-analysis was based on the PICO criteria.

How is this drug best taken?

The patient population (P) consisted of women with HSDD; the intervention (I) was the administration of flibanserin for managing HSDD; the control (C) included women receiving a placebo; and the outcomes (O) included the change from baseline (CFB) to study end in the number of SSE, among other outcomes. This analysis included RCTs with pre- or postmenopausal women aged ≥ 18 years and a diagnosis of HSDD. The trials had at least 2 treatment arms/groups, one receiving flibanserin and the other receiving a placebo. Exclusion criteria excluded animal or healthy human trials, nonrandomized trials, retrospective studies, blue 100 pill conference proceedings, letters to editors, case reports, and articles lacking data with outcomes of interest. The primary efficacy outcomes of this meta-analysis were the CFB to study end in the SSE per month and sexual desire score per month measured using an electronic diary (eDiary). (experimental drug) and placebo groups in the included studies.

Addyi is the #1 Prescribed Treatment by doctors for HSDD.1

[1] The fourth International Consultation on Sexual Medicine consensus statement asserts that, across a variety of assessment methods, the prevalence of women’s sexual complaints, regardless of age, is on the order of 40% to 50%. [2] Hypoactive sexual desire disorder (HSDD) is the most prevalent sexual complaint in women. HSDD is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised, as persistent deficient sexual fantasies and desire for sexual activity that causes marked fildena purple pill distress or interpersonal difficulty. [3] In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, HSDD has been replaced by Female Sexual Interest/Arousal Disorder, merging arousal and desire disorders. [4] It is estimated that about one in 10 women have HSDD.

Pediatric Precautions

The prevalence varies with age; 8.9% of women ages 18 to 44, 12.3% ages 45 to 64, and 7.4% >65 years have HSDD. [5] Despite its high prevalence, effective pharmacotherapy for HSDD is still limited. Only two medications, flibanserin and bremelanotide, have been approved by the United States Food and Drug Administration (US FDA) for treating HSDD in premenopausal women. Bremelanotide is a melanocortin 3 and 4 receptor agonist, taken as a subcutaneous injection before sexual activity. [1,5,6] The US FDA approved flibanserin, supported by findings from 3 randomized placebo-controlled trials involving premenopausal women with HSDD.